{"organizations": [], "uuid": "862b858820a8ad705cf439fb698c62a9411805df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180413.html", "section_title": "Archive News &amp; Video for Friday, 13 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-deinove-takes-on-a-whole-new-dimen/brief-deinove-takes-on-a-whole-new-dimension-with-the-acquisition-of-morphochems-clinical-stage-antibiotic-compound-idUSASO00038Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Deinove Takes On A Whole New Dimension With The Acquisition Of Morphochem's Clinical Stage Antibiotic Compound", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.559, "site_type": "news", "published": "2018-04-13T12:35:00.000+03:00", "replies_count": 0, "uuid": "862b858820a8ad705cf439fb698c62a9411805df"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-deinove-takes-on-a-whole-new-dimen/brief-deinove-takes-on-a-whole-new-dimension-with-the-acquisition-of-morphochems-clinical-stage-antibiotic-compound-idUSASO00038Z", "ord_in_thread": 0, "title": "BRIEF-Deinove Takes On A Whole New Dimension With The Acquisition Of Morphochem's Clinical Stage Antibiotic Compound", "locations": [], "entities": {"persons": [{"name": "biovertis", "sentiment": "none"}, {"name": "rphochem", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acquisition of morphochem", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "biovertis ag", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 13 (Reuters) - Deinove SA:\n* DEINOVE TAKES ON A WHOLE NEW DIMENSION WITH THE ACQUISITION OF MORPHOCHEM’S CLINICAL-STAGE ANTIBIOTIC COMPOUND\n* DEINOVE SA- ANNOUNCES ACQUISITION, THROUGH A CONTRIBUTION-IN-KIND TRANSACTION, OF ENTIRE CAPITAL OF AUSTRIAN COMPANY BIOVERTIS AG\n* DEINOVE SA- BIOVERTIS OWNS ENTIRE CAPITAL OF GERMAN COMPANY MORPHOCHEM, WITH LATTER DEVELOPING CLINICAL-STAGE ANTIBIOTIC COMPOUND “MCB3837” Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T12:35:00.000+03:00", "crawled": "2018-04-14T13:37:48.008+03:00", "highlightTitle": ""}